Chemoprevention for colon cancer: New opportunities, fact or fiction?

References

• Keighley MR. Gastrointestinal cancers in Europe. Aliment Pharmacol Ther 2003; 18(Suppl 3)7–30
   PubMedGoogle Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153–6
   PubMed Web of Science ®Google Scholar
• Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C, et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 2001; 3: 433–8
   PubMed Web of Science ®Google Scholar
• Clevers H. At the crossroads of inflammation and cancer. Cell 2004; 118: 671–4
   PubMed Web of Science ®Google Scholar
• Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–67
   PubMed Web of Science ®Google Scholar
• Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343: 162–8
   PubMed Web of Science ®Google Scholar
• Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. Br Med J 1998; 317: 559–65
   PubMed Web of Science ®Google Scholar
• Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119: 1219–27
   PubMed Web of Science ®Google Scholar
• Rengucci C, Maiolo P, Saragoni L, Zoli W, Amadori D, Calistri D. Multiple detection of genetic alterations in tumors and stool. Clin. Cancer Res 2001; 7: 590–3
   Google Scholar
• Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001; 93: 858–65
   PubMedGoogle Scholar
• Mathy C, Schneider K, Chen YY, Varma M, Terdiman JP, Mahadevan U. Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. Inflamm Bowel Dis 2003; 9: 351–5
   PubMed Web of Science ®Google Scholar
• Bernstein CN. Ulcerative colitis with low-grade dysplasia. Gastroenterology 2004; 127: 950–6
   PubMedGoogle Scholar
• Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526–35
   PubMed Web of Science ®Google Scholar
• Aitola P, Matikainen M, Mattila J, Tomminen T, Hiltunen KM. Chronic inflammatory changes in the pouch mucosa are associated with cholangitis found on peroperative liver biopsy specimens at restorative proctocolectomy for ulcerative colitis. Scand J Gastroenterol 1998; 33: 289–93
   PubMedGoogle Scholar
• Marchesa P, Lashner BA, Lavery IC, Milsom J, Hull TL, Strong SA, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997; 92: 1285–8
   PubMed Web of Science ®Google Scholar
• Clevers H. At the crossroads of inflammation and cancer. Cell 2004; 118: 671–4
   PubMed Web of Science ®Google Scholar
• Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001; 120: 1356–62
   PubMed Web of Science ®Google Scholar
• Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale – update based on new evidence. Gastroenterology 2003; 124: 544–60
   PubMed Web of Science ®Google Scholar
• Friedman S, Rubin PH, Bodian C, Goldstein E, Harpaz N, Present DH. Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology 2001; 120: 820–6
   PubMedGoogle Scholar
• Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107: 934–44
   PubMed Web of Science ®Google Scholar
• Lim CH, Dixon MF, Vail A, Forman D, Lynch DA, Axon AT. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003; 52: 1127–32
   PubMed Web of Science ®Google Scholar
• Itzkowitz SH, Present DH. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 314–21
   PubMed Web of Science ®Google Scholar
• Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228–33
   PubMed Web of Science ®Google Scholar
• Riddell RH. Grading of dysplasia. Eur J Cancer 1995; 31(A7–8)1169–1170
   Google Scholar
• Eaden JA, Ward BA, Mayberry JF. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc 2000; 51: 123–8
   PubMed Web of Science ®Google Scholar
• Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000; 60: 3333–7
   PubMed Web of Science ®Google Scholar
• Clevers H. At the crossroads of inflammation and cancer. Cell 2004; 118: 671–4
   PubMed Web of Science ®Google Scholar
• Bai J, Sui J, Demirjian A, Vollmer CM, Jr, Marasco W, Callery MP. Predominant Bcl–XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 2005; 65: 2344–52
   PubMed Web of Science ®Google Scholar
• Scaife CL, Kuang J, Wills JC, Trowbridge DB, Gray P, Manning BM, et al. Nuclear factor kappaB inhibitors induce adhesion-dependent colon cancer apoptosis: implications for metastasis. Cancer Res 2002; 62: 6870–8
   PubMed Web of Science ®Google Scholar
• Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285–96
   PubMed Web of Science ®Google Scholar
• Tuynman JB, Peppelenbosch MP, Richel DJ. COX-2 inhibition as a tool to treat and prevent colorectal cancer. Crit Rev Oncol Hematol 2004; 52: 81–101
   PubMed Web of Science ®Google Scholar
• Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci USA 2003; 100: 143–8
   PubMed Web of Science ®Google Scholar
• Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000; 60: 3333–7
   PubMed Web of Science ®Google Scholar
• Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci USA 2003; 100: 143–8
   PubMed Web of Science ®Google Scholar
• Chang CL, Marra G, Chauhan DP, Ha HT, Chang DK, Ricciardiello L, et al. Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol 2002; 283: C148–54
   PubMed Web of Science ®Google Scholar
• Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252–66
   PubMed Web of Science ®Google Scholar
• Tuynman JB, Peppelenbosch MP, Richel DJ. COX-2 inhibition as a tool to treat and prevent colorectal cancer. Crit Rev Oncol Hematol 2004; 52: 81–101
   PubMed Web of Science ®Google Scholar
• Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883–90
   PubMed Web of Science ®Google Scholar
• Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891–9
   PubMed Web of Science ®Google Scholar
• Ballinger A, Smith G. COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention. Expert Opin Pharmacother 2001; 2: 31–40
   PubMedGoogle Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–80
   PubMed Web of Science ®Google Scholar
• Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081–91
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–102
   PubMed Web of Science ®Google Scholar
• Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994; 107: 117–20
   PubMed Web of Science ®Google Scholar
• Moody GA, Jayanthi V, Probert CS, Mac KH, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1179–83
   PubMed Web of Science ®Google Scholar
• Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145–53
   PubMed Web of Science ®Google Scholar
• Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451–9
   PubMed Web of Science ®Google Scholar
• Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249–52
   PubMed Web of Science ®Google Scholar
• Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I, Schmiegel W. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 2003; 24: 443–51
   PubMed Web of Science ®Google Scholar
• Brown WA, Farmer KC, Skinner SA, Malcontenti-Wilson C, Misajon A, O'Brien PE. 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci 2000; 45: 1578–84
   PubMedGoogle Scholar
• Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997; 112: 29–32
   PubMed Web of Science ®Google Scholar
• Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 2004; 126: 1634–48
   PubMed Web of Science ®Google Scholar
• Kim YI. Role of folate in colon cancer development and progression. J Nutr 2003; 133: 3731S–9S
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses’ Health Study. Ann Intern Med 1998; 129: 517–24
   PubMed Web of Science ®Google Scholar
• Bailey LB, Rampersaud GC, Kauwell GP. Folic acid supplements and fortification affect the risk for neural tube defects, vascular disease and cancer: evolving science. J Nutr 2003; 133: 1961S–8S
   PubMed Web of Science ®Google Scholar
• Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184–92
   PubMed Web of Science ®Google Scholar
• Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000; 160: 2363–8
   PubMed Web of Science ®Google Scholar
• Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 89–95
   PubMed Web of Science ®Google Scholar
• Pardi DS, Loftus EV, Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889–93
   PubMed Web of Science ®Google Scholar
• Alberts DS, Martinez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005; 97: 846–53
   PubMed Web of Science ®Google Scholar
• Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. J Am Med Assoc 2002;288:321–33.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999; 106: 574–82
   PubMed Web of Science ®Google Scholar
• Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin 1993; 43: 7–26
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 1980; 65: 1201–7
   PubMed Web of Science ®Google Scholar
• Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994; 7: 536–40
   PubMed Web of Science ®Google Scholar
• Campagnoli C, Biglia N, Altare F, Lanza MG, Lesca L, Cantamessa C, et al. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol 1993; 7: 251–8
   PubMed Web of Science ®Google Scholar
• Logan RF, Rifkind EA, Turner ID, Ferguson A. Mortality in celiac disease. Gastroenterology 1989; 97: 265–71
   PubMed Web of Science ®Google Scholar
• Askling J, Linet M, Gridley G, Halstensen TS, Ekstrom K, Ekbom A. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology 2002; 123: 1428–35
   PubMed Web of Science ®Google Scholar
• West J, Logan RF, Smith CJ, Hubbard RB, Card TR. Malignancy and mortality in people with coeliac disease: population based cohort study. Br Med J 2004; 329: 716–19
   PubMed Web of Science ®Google Scholar